The community of Mt. Washington came together Tuesday to support pediatric cancer patients and survivors. Seth’s Squad hosted its fifth annual blood drive, Rise of the Donor, in collaboration with the ...

Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.

The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

Mabry was a toddler when her local doctors realized her best chance at survival would be St. Jude Children’s Research ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...

To know 8-year-old Brielle Ambabo is to love her. Her silly personality, upbeat attitude and countless jokes are sure to ...

Brunswick High School's "Brunswick for a Brighter Future" Student Visionaries team raised $168,000 for the Leukemia & ...

The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or ...

Zavier Sexton, Graham Smith, Bryce Miller and Natalie Vulhop were honored as young heroes at the 2025 CBJ Foundation ...

Treatment of B-cell Acute Lymphoblastic Leukaemia has been greatly improved by CAR-T therapies, but relapse is still very common. An international team has now found in animal models a new approach ...

Sana revolutionizes treatments for diabetes, cancer, and autoimmune diseases. SANA has high cash burn and dilution risks. See ...

Discontinuing tyrosine kinase inhibitor maintenance after extended complete molecular response should only be attempted as part of a clinical trial, the researchers say.